Fast Forward Therapeutic Innovation
March 17, 2026
Avanti Biosciences has been named a Connect San Diego 2026 Cool Company, recognized among San Diego's most promising venture-ready startups. Connect's Cool Companies program has supported over 100 companies since 2015, which have collectively raised more than $1 billion in funding. Avanti will participate in a series of showcase events, including a Private VC Showcase on April 15, 2026, and a Public Showcase on June 16, 2026, in San Diego.
​
February 17, 2026
Avanti Biosciences has been selected as a Hello Tomorrow Deep Tech Pioneer in the 11th Hello Tomorrow Challenge, recognized from 4,800+ applications across 108 countries. The company is now in the running to become a Finalist, with notification expected by mid-March 2026. If selected as a Finalist, Avanti will be invited to pitch at the Hello Tomorrow Summit in Amsterdam on June 11-12, 2026.
​
February 10, 2026
Avanti Biosciences has been selected to present at Biocom's sold-out Global Partnering & Investor Conference (GPIC), February 24–26, 2026, at The Lodge at Torrey Pines, San Diego. The company will present its clinical development strategy for ABI-171, the first therapy to demonstrate disease reversal in idiopathic pulmonary fibrosis (IPF).
​
December 2025
Avanti Biosciences has been awarded the NHLBI Catalyze Program by the National Heart, Lung, and Blood Institute (NIH). The program provides funding and regulatory support for IND-enabling studies, GMP manufacturing, and clinical trial preparation for ABI-171 in idiopathic pulmonary fibrosis (IPF).
​
December 2025
The U.S. Food and Drug Administration (FDA) has granted Avanti Biosciences a Pre-IND Type B meeting (PIND 180251) to discuss the clinical development plan for ABI-171 in idiopathic pulmonary fibrosis. Written responses are expected in March 2026.
​
July 18, 2024
Received orphan-drug designation from the FDA for our lead molecule, ABI-171, in the treatment of idiopathic pulmonary fibrosis (IPF).
​
July 23, 2023
Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK (1R43DK134232-01A1) for the development of new therapies for the treatment of liver diseases in collaboration with Ohio State University (Professor Richard Bruno)
​
May 5, 2019
Avanti Biosciences has been awarded the second phase of the fast-track SBIR grants from the NIA for its work on Alzheimer's Disease.
​
July 30, 2018
Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK for the development of new therapies for the treatment of Hyperinsulinemia Hyperammonemia Syndrome in collaboration with the Children's Hospital of Philadelphia (CHOP)
​
May 1, 2018
Avanti Biosciences open new operations in the JLAB San Diego.
​
August 15, 2017
Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s Disease
​
October 8, 2015